Many groundbreaking scientific discoveries never reach patients because they fail to attract capital or secure a commercial partnership. This "translation death" highlights that business development, not just R&D, is a critical bottleneck in delivering therapies to patients.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Since most biotech programs fail (as few as 1 in 10 succeed), a company's survival depends on running a portfolio of multiple programs simultaneously. This requires the discipline to quickly terminate unsuccessful projects and the foresight to have subsequent programs already underway.

True innovation requires leaders to adopt a venture capital mindset, accepting that roughly nine out of ten initiatives will fail. This high tolerance for failure, mirroring professional investment odds, is a prerequisite for the psychological safety needed for breakthrough results.

While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.

Stop chasing incremental improvements. An experienced founder's mindset is that 9 out of 10 experiments will fail or show only marginal gains, which is equivalent to failure. The goal is to run enough tests to find the 1-in-10 initiative that delivers exponential results and carries the business forward.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.

Small biotechs face a paradox: they must pursue highly innovative, risky science to differentiate themselves, as "me-too" drugs won't attract investment. The key to survival is managing this high scientific risk with strategies that provide fast, capital-efficient data for go/no-go decisions.